SCROLL
Company

L&J BIO is a clinical-stage biotechnology company advancing transformative therapies for neurodegenerative diseases.
Our lead asset, AL04, is in Phase 1 clinical trials in the USA, supported by a differentiated dual-action approach targeting amyloid beta and tau.
With three additional programs in development, we are building a diversified pipeline and pursuing global partnerships to drive meaningful value.

L&J BIO
Company Name
2012
Established
USA
Office & Laboratory (Maryland)
KOREA
Office & Laboratory (Seoul)
Locations
Core Business
Alzheimer’s Disease-Modifying Drug

(Amyloid Beta & p-Tau Target)

Management
CEO

Ho June Lee

CMO

Kwan Hee Lee (M.D., Ph.D.)

CFO, COO

Seunghwan Lee (MBA)

Who We Are
We are a company rooted in
love
– for family,
for humanity, and for the future where neurodegenerative diseases no longer steal what matters most. Guided by integrity and driven by science, we’re developing treatments that aim to preserve connection, protect memory, and bring lasting peace to the lives of patients and the people who love them.
What We Stand For
  • LOVE

    Driven by love for my family and humanity, we are a company dedicated to honest research.

  • Integrity

    We conduct honest research, unwavering in our principles and not swayed by short-term profits.

  • Clear

    We aim for ethical management and transparency in both our operations and research processes.

  • Sincerity

    We follow the core principles with responsibility, always striving to give our best effort.